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AG1478Sodium-proton exchanger type 1 (NHE-1) is ubiquitously expressed, is activated by numerous growth
factors, and plays signiﬁcant roles in regulating intracellular pH and cellular volume, proliferation and
cytoskeleton. Despite its importance, little is known about its regulation in renal glomerular podocytes. In the
current work, we studied the regulation of NHE-1 activity by the epidermal growth factor receptor (EGFR) in
cultured podocytes. RT-PCR demonstrated mRNAs for NHE-1 and NHE-2 in differentiated podocytes, as well
as for EGFR subunits EGFR/ErbB1, Erb3, and ErbB4. EGF induced concentration-dependent increases in
proton efﬂux in renal podocytes as assessed using a Cytosensor microphysiometer, were diminished in the
presence of 5-(N-methyl-N-isobutyl) amiloride or in a sodium-free solution. Furthermore, pharmacological
inhibitors of Janus kinase (Jak2) and calmodulin (CaM) attenuated EGF-induced NHE-1 activity. Co-
immunoprecipitation studies determined that EGF induced formation of complexes between Jak2 and CaM,
as well as between CaM and NHE-1. In addition, EGF increased levels of tyrosine phosphorylation of Jak2 and
CaM. The EGFR kinase inhibitor, AG1478, blocked activation of NHE-1, but did not block EGF-induced
phosphorylation of Jak2 or CaM. These results suggest that EGF induces NHE-1 activity in podocytes through
two pathways: (1) EGF→EGFR→ Jak2 activation (independent of EGFR tyrosine kinase activity)→ tyrosine
phosphorylation of CaM→CaM binding to NHE-1→conformational change of NHE-1→activation of NHE-1;
and (2) EGF→EGFR→EGFR kinase activation→association of CaM with NHE-1 (independent of
Jak2)→conformational change of NHE-1→activation of NHE-1.© 2009 Elsevier B.V. All rights reserved.1. Introduction
Epidermal growth factor (EGF) plays a number of key roles in the
kidney, contributing to cellular proliferative and survival pathways,
renal metabolism [1], regenerative hyperplasia [2], tubulointerstitial
injury [3], tubulogenesis [4], transport [5], renal cyst formation [6] and
renal development [7]. EGF also has been implicated in the genesis
and development of polycystic kidney disease [8,9]. Despite the
importance of EGF in many renal functions, particularly in renal
tubules and mesangial cells, little is known about its effects in
glomerular podocytes. Podocytes are critical for the maintenance of
normal glomerular structure [10,11], and aberrant podocyte function
has been implicated in the pathogenesis of chronic renal diseases
[12–17]. These highly specialized cells are characterized by the
formation of foot processes that are interconnected by the slit
diaphragm, which is a critical component of the glomerular ﬁltration
barrier [18,19]. Podocytes are emerging as the focus of intensearolina, Colcock Hall, Ofﬁce of
SA. Tel.: +1 843 792 3031; fax:
).
ll rights reserved.investigation because they have been implicated as both targets and
instigators of renal injury in various progressive renal diseases
[18,20–23]. Therefore, it would be desirable to elucidate signaling
pathways in podocytes, which may be important in delineating the
mechanisms through which podocytes contribute to the progression
of glomerular injury.
Because of the emerging role of the sodium-proton exchanger
type 1 (NHE-1), also known as product of SLC9A1, solute carrier
family 9A, type 1 in the regulation of the cytoskeleton [24], apoptosis
and cellular proliferation [25], cell cycle control [26], and develop-
ment and maintenance of the transformed cellular phenotype [27],
we thought that it might be of interest to develop a better
understanding of its regulation in podocytes. Previous studies have
demonstrated that EGF stimulates NHE-1 in non-renal cells [28–30],
but the signaling pathways involved in the regulation have not been
fully elucidated. Moreover, currently there are no data on the
regulation of NHE-1 in podocytes. In that regard, recent studies from
our laboratory have shown that NHE-1 can be activated by G
protein-coupled receptors or hypertonic medium, through Janus
kinase 2 (Jak2)-dependent phosphorylation of CaM, and subsequent
interaction between CaM and NHE-1 [31–33]. Therefore, we wanted
to determine whether EGF is important for regulating NHE-1 activity
Fig. 1. Immunoﬂuorescence analysis of podocyte markers. Cells were ﬁxed and then
stained for synaptopodin or WT-1 to conﬁrm differentiated from undifferentiated
podocytes. Undifferentiated podocytes did not stain for synaptopodin (A). In contrast,
differentiated podocytes stained for synaptopodin (B). Undifferentiated and differ-
entiated podocytes stained for WT-1 (C and D).
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transduction pathway linking EGF and NHE-1. In the current study,
we demonstrate that EGF stimulates NHE-1 activity in podocytes. In
addition, we have shown that Jak2 and CaM play critical roles in the
activation of NHE-1 by EGF in podocytes.
2. Materials and methods
2.1. Cell culture
The podocyte cell line was kindly provided by Dr. Peter Mundel of
Mt. Sinai School of Medicine. Podocytes were cultured as previously
described [34]. Undifferentiated podocytes were maintained in RPMI-
1640 medium containing 10 U/ml of mouse recombinant γ-
interferon, 10% FBS, 100 U/ml of penicillin and 100 μg/ml of
streptomycin at 33 °C in 95% air and 5% CO2. To induce differentiation,
podocytes were maintained in the same medium as undifferentiated
podocytes without γ-interferon at 37 °C in 95% air and 5% CO2 for
14 days. All experiments were conducted using differentiated
podocytes, unless stated otherwise.
2.2. Immunoﬂuorescence microscopy
Immunolabeling was performed as previously described [34]. Cells
were seeded in 35-mm collagen-coated glass-bottom culture dishes
(MatTek Corporation) and ﬁxed with 2% paraformaldehyde, 4%
sucrose in phosphate-buffered saline (PBS) for 10 min at room
temperature. Subsequently, cells were permeabilized with 0.3% Triton
X-100 (Sigma) in PBS for 5 min, following which nonspeciﬁc binding
sites were blocked with 2% fetal calf serum, 2% BSA and 0.2% gelatin in
PBS for 1 h. Incubations with the appropriate dilutions of primary and
secondary antibodies (as directed by the manufacturer) were
performed in blocking solution. The primary and secondary antibodies
used were: anti-WT1 (1:50) (Santa Cruz Biotechnology); anti-
synaptopodin (Research Diagnostics, Inc.) and Alexa Fluor 488 goat
anti-mouse IgG (Molecular Probes). Confocal microscopy was per-
formed using a Zeiss LSM 510 META laser-scanning microscope (Carl
Zeiss, Inc.).
2.3. Microphysiometry
NHE-1 activity studies were conducted on a Cytosensor micro-
physiometer as previously described for other cell types [32,35,36].
Cells were plated on transwell membranes (3 μm pore size, 12 mm
size) at a density of 300,000 cells per insert, and serum starved
overnight on the day prior to experimentation. On the day of the
experiment, the cells were washed with serum-free, bicarbonate-free
F-12 medium, prior to being placed into microphysiometer chambers.
The chambers were perfused at 37 °C with serum-free media or
balanced salt solutions. After establishment of a stable baseline for at
least ﬁve cycles, cells were exposed to the drugs for 4 cycles (360 s).
Podocytes had low basal proton efﬂux levels (−10 to −40 μV/s),
which roughly corresponds to millipH units/minute according to the
Nernst equation). The extracellular acidiﬁcation rate (ECAR, rate of
accumulation of protons during a stop-ﬂow period) was measured at
peak stimulation after initiation of drug treatment, as is standard for
microphysiometry studies. This typically occurred after two or three
cycles (180 or 270 s) of exposure to EGF. Rate data were expressed as
percentages of baseline values.
2.4. RT-PCR and PCR
RNA was prepared from differentiated and undifferentiated
podocytes using Trizol reagent following the manufacturer's protocol
(Invitrogen). Five micrograms of total RNA were used for ﬁrst strand
cDNA synthesis (SuperScript III RT-PCR kit, Invitrogen). EGFR/ErbBtranscripts were identiﬁed using SuperArray's Multigen-12 RT-PCR
proﬁling kit. To analyze NHE-1 message an already published primer
pair was used: 5′-TCTGCCGTCTCAACTGTCTCTA-3′ sense, 5′-
CCCTTCAACTCCTCATTCACCA-3′ antisense [37], which generated a
422 base pair (bp) product. For analyzing other NHE messages, new
PCR primer pairs were designed: NHE-2 (5′-ACACACAACATCCGGGT-
CATT-3′ sense, 5′-CGCTTGTGTCTGCCGTCA-3′ antisense) resulted in a
982 bp product; NHE-3 (5′-CGCCTGGAGTCCTTTAAGTC-3′ sense, 5′-
GGAGAACACGGGATTATCAAT-3′ antisense) generated a 294 bp pro-
duct, and NHE-4 (5′-GAGGACATAGAAGCGGTGGAC-3′ sense, 5′-
AGGAGAAAGCCGCTTGATTC-3′ antisense) resulted in a 993 bp PCR
product. Target speciﬁcities of the PCR primers were conﬁrmed by
sequencing the PCR products using the MUSC sequencing core facility.
2.5. Immunoprecipitation
For immunoprecipitation of Jak2 and NHE-1, quiescent differ-
entiated podocytes grown on 100 mm collagen-coated tissue culture
dishes were pretreated with 50 μM of AG490 or 20 μM of AG1478 for
30 min prior to treatment with 10 ng/ml of EGF or vehicle for 5 min,
and then lysed in 1 ml/dish of RIPA buffer (50 mM Tris–HCl, pH 7.4,
150 mM NaCl, 0.25% deoxycholic acid, 1% NP-40, 1 mM EDTA)
supplemented with protease inhibitors (1 mM AEBSF, 0.8 μM
aprotinin, 50 μM bestatin, 15 μM E-64, 20 μM leupeptin, 10 μM
pepstatin A, 1 mM sodium orthovanadate, 1 mM sodium ﬂuoride and
1 mM PMSF). Equal amounts of proteins (1.5 mg) were precleared by
incubation with protein A/G sepharose beads for 30 min at 4 °C.
After a brief centrifugation, the supernatants were removed and
incubated with either agarose conjugated anti-JAK2 antibody
(Upstate) or anti-NHE-1 antibody (Chemicon) overnight at 4 °C.
Immunoprecipitates were captured with 50 μl of protein A/G beads
at 4 °C for 1 h. Then, the samples were centrifuged and washed
Fig. 2. Presence of functional EGFR in podocytes. (A) RT-PCR analyses of EGFR/ErbB
receptor subunit mRNA expression. Expression of different EGFR subunits in
undifferentiated and differentiated podocytes is shown: EGFR (183 bp), Neu/HER2
(130 bp), ErbB3 (153 bp) and ErbB4 (204 bp). (B) Microphysiometry was used to
analyze the concentration-dependent effects of EGF on extracellular acidiﬁcation
rate (ECAR) in podocytes. Independent experiments were performed a minimum
of three times in triplicate, and the data are presented as mean±SEM of
peak values.
Fig. 3. EGF stimulates NHE-1 activity in podocytes. (A) RT-PCR analysis of NHE
isoforms. Expression of different NHE isoform mRNAs in (a) whole mouse kidney
lysates; (b) undifferentiated podocytes; and in (c) differentiated podocytes are
shown: NHE-1 (422 bp), NHE-2 (982 bp), NHE-3 (294 bp) and NHE-4 (993) bp. (B)
Microphysiometry was used to characterize EGF-induced increases in ECAR.
Podocytes were stimulated with 10 ng/ml of EGF in the presence or absence of
sodium-free medium or MIA (a NHE-1 inhibitor). Values depicted are mean±SEM of
peak values from 3 independent experiments performed in triplicate. ⁎⁎Pb0.01 vs
drug alone samples.
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the beads using 2× Laemmli sample buffer. Samples subsequently
were separated by SDS-PAGE and transferred to PVDF membrane.
Blots were probed with anti-calmodulin antibody (Upstate), and, to
ensure equal NHE-1 and Jak-2 precipitation from the samples, with
NHE-1 monoclonal antibody (Chemicon) or Jak-2 antiserum
(Upstate).
For phosphotyrosine immunoprecipitation experiments, quies-
cent podocytes grown onto 100 mm collagen-coated tissue culture
dishes were pretreated with AG-490 (50 μM), or with AG-1478
(20 μM) or vehicle for 30 min, then stimulated with 10 ng/ml EGF
or vehicle for 5 min and lysed in 0.5 ml/100 mm dish of RIPA
buffer (150 mM NaCl, 50 mM Tris–HCl, pH 7.4, 1 mM EDTA, 1%
Nonidet P-40, 1 mM NaF, 1 mM Na3VO4, 1 mM phenylmethylsulfo-
nyl ﬂuoride, aprotinin, leupeptin, and pepstatin at 1 μg/ml each).
Cell lysates were precleared by incubating with protein A-agarose
bead slurry for 30 min at 4 °C. Precleared lysates (1 μg/μl total cell
protein) were incubated with monoclonal anti-phosphotyrosine
antibody conjugated to protein A-agarose (Cell Signaling) overnight
at 4 °C. The agarose beads were collected by centrifugation, washed
twice with RIPA buffer and once with PBS, resuspended in 2×
Laemmli sample buffer, boiled for 5 min, and subjected to SDS-
PAGE and subsequent immunoblot analyses with polyclonal anti-
phosphotyrosine, anti-EGFR, anti-Jak2, or with monoclonal anti-
CaM antibodies (Upstate).
2.6. Statistical analysis
Data were analyzed by paired, two-tailed Student's t test and
analysis of variance using GraphPad Statistics Software. P valuesb0.05
were considered signiﬁcant.3. Results
3.1. Immunohistochemical conﬁrmation of podocyte differentiation
Podocytes were stained for WT-1 and synaptopodin. Undiffer-
entiated podocytes did not stain for synaptopodin (Fig. 1, Panel A);
however, the cells did stain for WT-1 (Fig. 1, Panel C). Differentiated
podocytes stained for synaptopodin (Fig. 1, Panel B) and WT-1 (Fig. 1,
Panel D). The results of the staining conﬁrm that in our hands, the
cultured podocytes showed hallmarks of differentiation.
3.2. EGFR mRNAs are expressed in podocytes
Epidermal growth factor (EGF) receptors constitute a family of
four prototypical receptor tyrosine kinases (ErbB1-4). EGF receptor
(EGFR) subunits dimerize upon ligand binding, resulting in the
formation of activated receptors. We determined which EGFR
subunit mRNAs were expressed in podocytes using RT-PCR.
Undifferentiated podocytes expressed the mRNAs for EGFR/ErbB1,
Neu/HER2, ErbB3, and ErbB4 (Fig. 2A). Differentiated podocytes
expressed the mRNAs for EGFR/ErbB1, Erb3, and ErbB4. Neu/HER2
mRNA was detectable at very minute levels in differentiated
podocytes (Fig. 2A).
3.3. EGF induces concentration-dependent increases in ECAR
Having established that podocytes express EGFR mRNAs, we next
determined whether the cells expressed functional EGFR. We
measured EGF-induced increases in extracellular acidiﬁcation rates
using microphysiometry under stop-ﬂow conditions. Fig. 2B shows
that EGF increased proton efﬂux in a concentration-dependent
1177S.D. Coaxum et al. / Biochimica et Biophysica Acta 1793 (2009) 1174–1181manner, conﬁrming the presence of functional EGFR in differen-
tiated podocytes.
3.4. EGF activates Na+/H+ exchange in podocytes
We next sought to determine the nature of the proton efﬂux
pathway activated by EGF. Because EGF has been shown to stimulate
sodium-proton exchangers in ﬁbroblasts, esophageal epithelia and
chondrocytes [30,38–40], we studied the expression of mRNAs
encoding plasma membrane localized sodium-proton exchangers
NHE-1, NHE-2, NHE-3, and NHE-4. Fig. 3A shows that differentiated
podocytes express mRNA for NHE-1 and NHE-2, with the levels of
NHE-1 mRNA predominating. Undifferentiated podocytes express
only the mRNA for NHE-1 (Fig. 3A). The mRNAs for NHE-3 and NHE-4
were not detected in undifferentiated or differentiated podocytes.
Thus, it is possible that EGF-mediated proton efﬂux from differ-
entiated podocytes involves NHE-1 or NHE-2.
In order to test the involvement of sodium-proton exchangers in
the stimulation of proton efﬂux by EGF, we isotonically substituted
tetramethylammonium (TMA) for sodium in the extracellular perfu-
sate, thereby removing the extracellular substrate for sodium-proton
exchangers. Fig. 3B shows that EGF stimulated proton efﬂux in a
medium containing sodium, and that this effect was nearly abolishedFig. 4. Effects of CaM inhibitors and tyrosine kinase inhibitors on EGF-induced ECAR in
podocytes. Microphysiometry was used to measure ECAR in podocytes. (A) Podocytes
were pretreated with CaM inhibitors for 30 min prior to stimulation with 10 ng/ml of
EGF. (B) Podocytes were pretreated with AG1478 (20 μM) or AG490 (50 μM) for
30 min prior to stimulation with 10 ng/ml of EGF. Values are mean±SEM of peak
values from 3 independent experiments performed in triplicate. ⁎Pb0.05; ⁎⁎Pb0.01 vs
drug alone samples.
Fig. 5. EGF induces formation of signaling complexes between Jak2 and CaM, and NHE-1
and CaM in podocytes. Co-immunoprecipitation experiments were performed as
described under Materials and methods. (A) Podocytes were pretreated with AG-490
(50 μM), or with AG-1478 (20 μM), or vehicle for 30 min, and then stimulated with
10 ng/ml of EGF for 5 min prior to being immunoprecipitated with agarose conjugated
anti-Jak2 antibody and then immunoblotted with anti-CaM or anti-Jak2 antibody. The
insert is a representative immunoblot (CaM). The same blot was stripped and re-probed
with antibodies for total Jak2 to ensure an equal loading of proteins (Jak2). (B) After
stimulation of podocytes with 10 ng/ml of EGF for 10 min in the presence or absence of
AG490 (50 μM) or AG1478 (20 μM), precleared cell lysates were immunoprecipitated
with agarose conjugated anti-NHE-1 antibody and then immunoblotted with anti-
calmodulin or anti-NHE-1 antibody. Values are mean±SEM from 3 independent
experiments. ⁎Pb0.05 vs control, ‡Pb0.05 vs EGF.in medium inwhich sodiumwas replaced by TMA. In addition, 5 μMof
5-(N-methyl-N-isobutyl) amiloride (MIA), an inhibitor of NHE-1 and
NHE-2, attenuated EGF-induced proton efﬂux by nearly 60% (Fig. 3B).
These ﬁndings suggest that EGF-induced increases in ECAR are due to
NHE-1 or NHE-2 in podocytes.
3.5. Calmodulin inhibitors, phosphotyrosine inhibitors and Jak2
inhibitors attenuate EGF-induced NHE-1 activity
NHE-1 has two CaM-binding domains that are critical for its
activation by many stimuli [41,42], whereas the role of CaM in the
regulation of NHE-2 is much less certain [43]. Although elevations of
intracellular calcium increase the activity of NHE-2 [43], CaM has been
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CaM is involved in EGF induced increases in ECAR, we analyzed the
effects of a panel of CaM inhibitors on EGF-induced proton efﬂux in
podocytes. The results in Fig. 4A demonstrate that W-7, ﬂuphenazine,
and ophiobolin A, each inhibited EGF-induced increases in ECAR by
≥60%. Because none of those agents reduced the basal levels of proton
efﬂux in podocytes, the results aremost consistent with EGF activation
of NHE-1.
Because previous studies from our laboratory demonstrated that
Jak2 is important for NHE-1 activation by hypertonicity and by Gq-
coupled receptors [32,33], we analyzed the effects of a Jak2 inhibitor,
AG490, on EGF-induced activation of NHE-1 in podocytes. AG490
(50 μM) inhibited EGF-induced increases in ECAR by N50% (Fig. 4B).
The EGFR tyrosine kinase inhibitor AG1478 (20 μM) also inhibited
ECAR in podocytes that were stimulated with EGF by N95%. These
results support the involvement of Jak2 and the EGFR in the EGF-
induced increases in ECAR.Fig. 6. Tyrosine phosphorylation of Jak2 and CaM in response to EGF treatment of podocytes. C
methods. (A) Podocytes were pretreated with AG-490 (50 μM), or with AG-1478 (20 μM), o
being immunoprecipitated with anti-phosphotyrosine/protein A-agarose, and then immun
(B). (C) To determine if CaM was tyrosine phosphorylated, podocytes were stimulated with
(20 μM) or vehicle for 30 min, immunoprecipitated with monoclonal anti-phosphotyrosin
monoclonal anti-CaM antibody. The same blots were stripped and re-probed with polyclon
stimulation with EGF (not shown). Values are mean±SEM from 5 independent experimen3.6. EGF increases formation of complexes of Jak2 and NHE-1 with CaM
To further examine a role for Jak2 in EGF-induced signaling, we
determined whether EGF stimulates the formation of signaling
complexes between Jak2, NHE-1, and CaM. To explore this possibility,
we performed co-immunoprecipitation experiments using cell lysates
from podocytes pretreated with vehicle or with inhibitors of Jak2 or
EGFR tyrosine kinases. Fig. 5A shows that CaM was present in Jak2
immunoprecipitates, and that the amount of CaM present in these
immunoprecipitates was doubled after EGF stimulation. Pretreatment
of cells with a Jak2 inhibitor, AG-490 (50 μM for 30 min) signiﬁcantly
decreased the amount of CaM in Jak2 immunoprecipitates, whereas
pretreatment with an EGFR kinase inhibitor, AG1478 (20 μM for
30 min) did not have such effect. This result suggests that EGF-
induced Jak2 activity (but not EGFR kinase activity) is necessary for
formation of the complex between Jak2 and CaM. In addition, Fig. 5B
shows that there was a marked increase in the amount of CaM in NHE-o-immunoprecipitation experiments were performed as described underMaterials and
r vehicle for 30 min, and stimulated with 10 ng/ml of EGF for 5 min prior to cell lysates
oblotted with polyclonal anti-EGFR antibody (A), or with polyclonal anti-Jak2 antibody
10 ng/ml of EGF for 5 min after pretreatment with AG-490 (50 μM), or with AG-1478
e (PY) antibody conjugated with protein A-agarose and then immunoblotted with a
al PY antibody to conﬁrm that CaM is indeed tyrosine phosphorylated in response to
ts. ⁎Pb0.05 vs control, ‡Pb0.05 vs EGF.
Fig. 7. Schematic representation of two converging pathways of activation of NHE-1 in
podocytes by EGF. P-CaM indicates tyrosine phosphorylated CaM. All other abbrevia-
tions are as described in the text.
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not an increased formation of complexes between Jak2 and NHE-1 in
podocytes after treatment with EGF (not shown). Pretreatment of
cells with a Jak2 inhibitor, AG490 (50 μM) or EGFR kinase inhibitor,
AG1478 (20 μM) decreased the amount of CaM in NHE-1 immuno-
precipitates. The latter result suggests that both EGFR kinase activity
and Jak2 activity are required to induce formation of a complex
between CaM and NHE-1.
3.7. EGF induces tyrosine phosphorylation of Jak and CaM
In order to examine further the signaling mechanisms involved in
the activation of NHE-1 by EGF, we next considered that EGF could
stimulate tyrosine phosphorylation of CaM. The data presented in
Fig. 6 (panel A) demonstrate that EGF increased the amount of EGFR
in phosphotyrosine immunoprecipitates, and that this effect is
unchanged in the presence of Jak2 inhibitor, but is completely
abolished after pretreatment with AG1478. This result demonstrates
that AG1478 effectively inhibits intrinsic EGFR tyrosine kinase
activity in podocytes. Fig. 6 (panel B) shows that EGF induces
tyrosine phosphorylation of Jak2, which is inhibited by pretreatment
with AG-490, but not with AG-1478. These results provide strong
evidence that EGF induces tyrosine phosphorylation of EGFR and
Jak2 via auto-phosphorylation of these kinases, and also demon-
strate that AG-490 and AG-1478 were effective under our experi-
mental conditions. The results also suggest that EGFR kinase activity
is not required for Jak2 activation by EGF. Fig. 6 (panel C) demonstrates
that EGF increases the amount of CaM in phosphotyrosine immuno-
precipitates and that this effect can be signiﬁcantly decreased by
pretreatment of cells with AG-490, but not with AG-1478, suggesting
that tyrosine phosphorylation of CaM is induced by Jak2, and does not
require EGFR kinase activity. In that regard, we demonstrated
previously that CaM is a bona ﬁde substrate for Jak2 [31].
4. Discussion
What is new about this work is that we have demonstrated that
EGF activates NHE-1 through the intermediary actions of Jak2 and
CaM in renal podocytes. The work expands recent studies demon-
strating that hypertonicity and Gq-coupled receptors activate NHE-1
in several cell types through a pathway involving sequential
phosphorylation and activation of Jak2, tyrosine phosphorylation of
CaM, CaM binding to NHE-1, and activation of NHE-1. The current
work is signiﬁcant in that we have (1) demonstrated that a
prototypical receptor tyrosine kinase (the EGFR) utilizes this pathway
and a second pathway, both of which are required for full activation of
NHE-1; (2) reﬁned the previously identiﬁed pathway as follows:
EGF→EGFR→ Jak2 activation (independent of EGFR tyrosine kinase
activity)→ tyrosine phosphorylation of CaM→CaM binding to NHE-
1→activation of NHE-1; (3) characterized a second activation
pathway as follows: EGF→EGFR→EGFR kinase activation→associa-
tion of CaM to NHE-1 (independent of Jak2)→activation of NHE-1
(Fig. 7). (4) We also have identiﬁed mRNAs for various isotypes of
plasma membrane NHEs, and for EGFR-related subunits, in renal
podocytes. Because podocytes have been implicated as playing key
roles in the initial stages of various glomerular diseases, this new
information may have relevance to the processes that link podocyte
dysfunction to progressive renal diseases.
The evidence implicating Jak2 in the increase in proton efﬂux is
that (1) Jak2 is activated as demonstrated by its tyrosine phosphor-
ylation in response to EGF, (2) AG490 blocks the increased proton
efﬂux induced by EGF, and (3) Jak2 forms a complex with CaM in
response to EGF. Although our work does not prove deﬁnitively that
tyrosine phosphorylation of Jak2 is required for activation of NHE-1 by
EGF, this seems likely in that (1) EGF does not increase intracellular
calcium levels under our conditions (data not shown), (2) CaM istyrosine phosphorylated through a pathway that is inhibited by
AG490, and (3) CaM is a bona ﬁde substrate for Jak2 [31].
The evidence implicating CaM in the increase in proton efﬂux is
that (1) a panel of CaM inhibitors greatly attenuates the increased
proton efﬂux induced by EGF, (2) CaM is tyrosine phosphorylated in
response to EGF, and (3) CaM is induced to form complexes with Jak2
and NHE-1 in response to EGF. The evidence that the proton efﬂux is
mediated by NHE-1 is that it is (1) dependent upon extracellular
sodium, (2) inhibited by MIA, (3) dependent upon CaM activity, and
(4) associated with increased binding of CaM to NHE-1.
The precise mechanism through which Jak2 activates NHE-1 has
not been fully elucidated. We propose that Jak2 tyrosine phosphor-
ylates CaM, thereby increasing its afﬁnity for NHE-1. This would result
in increased binding of CaM to NHE-1. A number of kinases have been
shown to phosphorylate CaM on serine, threonine and tyrosine
residues [44,45], and to alter the activity of CaM with reference to
speciﬁc CaM targets [46]. In that regard, our group has recently
demonstrated that CaM is directly tyrosine phosphorylated by
puriﬁed Jak2 [31]. Thus, Jak2 almost certainly phosphorylates CaM
on one or both of the tyrosine residues within the CaM sequence, Tyr-
99 and Tyr-138. Based on the crystal structure of CaM, Tyr-99 is the
more likely target for phosphorylation in that Tyr-99 is located within
the third Ca2+-binding domain, and is somewhat more exposed than
is Tyr-138 [45]. However, Jak2-induced tyrosine phosphorylation of
CaM appears to be critical or necessary, but not sufﬁcient to fully
activate NHE-1, because EGFR tyrosine kinase activity also is required.
Indeed, the effectiveness of AG1478 to block NHE-1 activation
suggests that EGFR tyrosine kinase activity also is essential for CaM
to bind to NHE-1 and to activate it. It should be noted that we have not
formally tested the idea that CaM binding to NHE-1 induces a
conformational change that results in activation of NHE-1. However,
this idea is intuitively pleasing, and has been supported by experi-
mental evidence in the form of mutation studies by [43], and by
solution phase spectroscopy studies of the interaction between CaM
and the large regulatory intracellular carboxyl terminus of NHE-1 by
Fliegel's group [41].
It is important to elaborate on our ﬁndings that the EGFR kinase
inhibitor AG1478 did not decrease the amount of Jak2 and CaM in
phosphotyrosine immunoprecipitates (Fig. 5B and C, respectively),
which suggests that there is another factor that allows EGF to regulate
tyrosine phosphorylation of CaM independent of EGFR kinase activity.
This ﬁnding is supported by previous reports that suggest that some
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of EGFR kinase activity [47,48]. Two groups demonstrated that
AG1478-independent effects of EGF might be mediated by ErbB2
(Neu/HER2), possibly through oligomerization with ErbB1/EGFR
[47,48]. It is unlikely that this mechanism can account for our ﬁndings
in that we detected little to no Neu/HER2 mRNA in differentiated
podocytes (Fig. 2A).
An alternative explanation for the dual Jak2- and EGFR tyrosine
kinase-dependent pathways of activation of NHE-1 is that both EGFR
and Jak2 could tyrosine phosphorylate CaM. This idea is reasonable
because the EGFR has been shown to phosphorylate CaM on Tyr-99
and/or Tyr-138 in other cell systems [44,49]. Indeed, the EGFR
possesses a juxtamembrane CaM-binding motif at residues 624–639,
which Martin-Nieto and Villalobo demonstrated could bind to CaM in
a calcium-dependent manner, with an afﬁnity of ≈400 nM [50].
However, it seems unlikely that the EGFR directly phosphorylates CaM
in podocytes in that the Jak2 inhibitor, AG490, signiﬁcantly suppresses
EGF-induced tyrosine phosphorylation of CaM, whereas AG1478 has
no signiﬁcant effect (Fig. 6B).
Because AG1478 attenuates ECAR more than CaM or Jak2
inhibitors, it appears that the receptor tyrosine kinase activity of
EGFR might be a bit more necessary than the non-receptor tyrosine
kinase pathway involving Jak2-CaM for activating NHE-1. Both
pathways clearly converge upon the physical association of NHE-1
and CaM, and are required for effective activation of NHE-1.
Additionally, because isotonic substitution of sodium with TMA
more effectively attenuates EGF-stimulated ECAR than does MIA, it
is possible that there is another sodium-dependent proton efﬂux
pathway that is insensitive to 5 μMMIA. The possibility is the subject
of future work.
What is the signiﬁcance of our ﬁndings to podocyte biology?
Although the signiﬁcance of EGF and/or NHE-1 in podocyte biology is
not known, we speculate that NHE-1 could participate in the
regulation of the cytoskeleton of podocytes, as NHE-1 is indirectly
tethered to, and regulates, the actin cytoskeleton of ﬁbroblasts [24].
NHE-1 is intimately linked to cytoskeletal regulatory proteins such as
Rho, and NHE-1 can regulate cytoskeletal architecture through both
ion channel regulation and protein–protein interaction [24]. Inasmuch
as the structural integrity of the cytoskeleton of podocytes is critical
for maintaining the podocyte foot processes and the glomerular slit
diaphragm, key cytoskeletal regulatory proteins like NHE-1 clearly
could play key roles in maintaining or regulating glomerular
architecture and protein permeability. Further work would be
necessary to test this possibility. NHE-1 also has been implicated in
cellular proliferation and apoptosis [25], so it could also play complex
roles in podocyte physiology and pathophysiology. EGF is a mitogen
and cell survival factor that also regulates regenerative hyperplasia [2].
Thus, it could regulate important podocyte functions independently
of, or in concert with NHE-1.
We conclude that EGF stimulates NHE-1 activity in podocytes
through two pathways, each of which is required for signiﬁcant
activation to occur (Fig. 7). These pathways converge upon CaM,
being essential for its physical engagement with NHE-1. The ﬁrst can
be depicted as follows: EGF→EGFR→ Jak2 activation (independent
of EGFR tyrosine kinase activity)→ tyrosine phosphorylation of
CaM→CaM binding to NHE-1→activation of NHE-1; and the
second pathway as follows: EGF→EGFR→EGFR tyrosine kinase
activation→ association of CaM to NHE-1 (independent of
Jak2)→activation of NHE-1 (Fig. 7).
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